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INTRODUCTION
Atypical amyloid generation, folding,
aggregation and impaired clearance
are characteristic pathological features
of human neurodegenerative disorders
including Alzheimer’s disease (AD). What
is generally not appreciated is that a major
secretory product of microbes is amyloid,
and that the contribution of microbial
amyloid to the pathophysiology of the
human central nervous system (CNS) is
potentially substantial. While earlier find-
ings suggested that these amyloids may
serve some immune-evasive strategy, it has
recently become evident that humans have
a tremendously heavy systemic burden
of amyloid which may contribute to the
pathology of progressive neurological dis-
eases with an amyloidogenic component.
This perspective will highlight some recent
inroads made into our understanding of
the enigmatic role that microbial amyloids
may play in the homeostasis and pathol-
ogy of the CNS with particular reference
to AD wherever possible.
AMYLOID: MICROBIAL AND CNS
SOURCES
“Amyloid” is a generic term for any aggre-
gated, insoluble, lipoprotein-rich deposit
exhibiting β-pleated sheet structures
oriented perpendicular to the fibril-
lar axis (Steensma, 2001; Badtke et al.,
2009; Blanco et al., 2012; Buxbaum and
Linke, 2012). Amyloids are character-
ized by an apple-green birefringence
(λmax ∼555 nm) when stained with
the secondary diazo-dye Congo-red
(λmax ∼498 nm) when viewed under
polarized light (upon binding to amyloid,
Congo Red displays bright fluorescence
emission at λmax ∼614 nm after exci-
tation at λmax ∼497 nm; Alexandrov
et al., 2011; O’Brien and Wong, 2011).
Amyloid fibrillation is initiated by
self-aggregation of protein monomers-
into-dimers, oligomers and fibrils, which
accumulate over time, and this process is
thought to result from the hydrophobic
nature of the aromatic amino-acid pep-
tides comprising the primary sequence of
the amyloid (O’Brien and Wong, 2011;
Lukiw, 2012). The Congo red dye-based
intercalation of β-pleated sheets, induction
of a positive anisotropy that is polarized
and directionally dependent, and gener-
ation of a measureable wavelength shift
and apple-green birefringence is the hall-
mark of all amyloids and is the “gold
standard” in the diagnosis of amyloido-
genic disease (Linke, 2006; Buxbaum and
Linke, 2012). The polymerization of amy-
loidogenic proteins is cooperative, and
can be accelerated by amyloid aggre-
gates derived from the same protein in
a selective “seeding” process. The identifi-
cation of the “amylome,” a classification
of amino acid sequences within pro-
teins with internal, self-complementary
interfaces and high fiber-forming propen-
sity has improved our understanding of
the capability of different proteins to
form amyloids that contribute to “dense-
deposit” disease (Goldschmidt et al.,
2010; O’Brien and Wong, 2011; Lukiw,
2012). The pathogenesis of diseases that
accumulate amyloid, including AD, all
involve a marked inflammatory response
at sites of amyloid deposition, and this
is mediated by microglial cells, the “rov-
ing macrophages” of the CNS. Microglia
appear to utilize molecular sensors on
their external surface, such as the Toll-like
receptor 2, TLR2, to recognize abnormal
forms of amyloid and initiate a phago-
cytic or “clearance” response (Zhao et al.,
2013; Ferrera et al., 2014; Jones et al.,
2014). Here we describe a relatively recent
collection of stimulating research at the
crossroads of microbial and AD amy-
loids highlighting 5 recent, specific and
illustrative insights into the potential con-
tribution of microbial-derived amyloids to
CNS amyloidogenesis and AD.
MICROBIOME-DERIVED AMYLOIDS
The microbiome is the aggregate of all
microorganisms that reside on and within
the human body, forming a complex
ecosystem that includes the skin, oral and
nasal mucosa, the urogenital and gastroin-
testinal (GI) tracts. The microbiome of
the GI tract is by far the largest reser-
voir of microbes in the human body,
containing about 1014 microbes; over
99% of microbiota in the GI tract are
anaerobic bacteria, with fungi, protozoa,
archaebacteria and other microorganisms
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making up the remainder (Bhattacharjee
and Lukiw, 2013; Hill et al., 2014; Lin
et al., 2014). Prokaryotic cells of the
human microbiome outnumber human
eukaryotic host cells by about 100 to
1, and collectively microbial genes out-
number host genes by about 150 to
1 (Hill et al., 2014; Lin et al., 2014).
Recent microbiome analysis has revealed
that the majority (98%) of all GI tract
species belongs to only 4 major bacte-
rial divisions: the gram-positive Firmicutes
(64%) and Actinobacteria (3%) and the
gram-negative Bacteroidetes (23%) and
Proteobacteria (8%). The remaining 2%
consist of minor taxonomic divisions
which are quite diverse (Hattori and
Taylor, 2009; Bhattacharjee and Lukiw,
2013; Schwartz and Boles, 2013). Many
different microbiome species including
fungi and bacteria secrete amyloid (Hill
et al., 2014; Syed and Boles, 2014). For
example, amyloids are associated with
fungal surface-structures and the recent
observation of amyloidogenic fungal pro-
teins and diffuse mycoses in the blood of
AD patients suggest that chronic fungal
infection increases AD risk (Alonso et al.,
2014a,b; Hill et al., 2014). To cite one other
recent example, in Escherichia coli extra-
cellular amyloids known as curli fibers,
composed of the major structural sub-
unit CsgA, are a common secretory com-
ponent that facilitate surface attachment
and adhesion, biofilm development and
protection against host defenses (Schwartz
and Boles, 2013; Asti and Gioglio, 2014).
Biofilms represent a matrix of extracellular
polymeric amyloids and other lipoproteins
in various structural forms. Interestingly,
the extracellular 17.7 kDa CsgA amyloid
precursor contains a pathogen-associated
molecular pattern (PAMP) that, like the
Aβ42 peptide, is recognized by the human
immune system TLR2 (Zhou et al., 2012).
An expanding list of bacterial amyloid sys-
tems include those associated with gram-
negative species of Streptomyces, Bacillus,
Pseudomonas, Staphylococcus and others,
suggesting that functional amyloids are
a widespread phenomenon utilized by
a wide diversity of microbiome-bacteria
(Schwartz and Boles, 2013; Asti and
Gioglio, 2014; Hill et al., 2014). Indeed
the extremely large number and vari-
ety of microbiome bacteria and their
capability to produce vast quantities of
amyloids indicates that human physi-
ology may be potentially exposed to
a tremendous systemic amyloid burden,
especially during aging when the GI
tract epithelial and blood-brain barriers
become significantly more restructured
and permeable (Bhattacharjee and Lukiw,
2013; Marques et al., 2013; Oakley and
Tharakan, 2014).
THE AMYLOID PEPTIDES OF AD AND
ENDOTOXIN-MEDIATED INFLAMMATION
A∼770 amino acid type 3 transmembrane
β-amyloid precursor protein (βAPP),
through interaction with membrane pro-
teins and tandem secretase cleavage yields
a series of ragged Aβ peptide monomers,
two of the most abundant being the 40
and 42 amino acid peptides Aβ40 and
Aβ42 (Van Broeck et al., 2007; O’Brien
and Wong, 2011; Zhang et al., 2012).
Aβ40 peptides associate with the endothe-
lium of the cerebral vasculature, and
the more neurotoxic, albeit less abun-
dant, hydrophobic Aβ42 species form the
nuclei of the senile plaque (SP) lesions
of AD (Alexandrov et al., 2011; O’Brien
and Wong, 2011). Interestingly, the extra
two hydrophobic amino acids in Aβ42
(vs. Aβ40) appear to convey many of
the toxic biophysical attributes and self-
aggregation of this slightly larger molecule
(Zhou et al., 2011; Teng et al., 2012;
Zhang et al., 2012). The recognition of
Aβ42 peptides and their misfolded aggre-
gates by microglial-surveillance systems,
and the inability of microglial cells to
deal with these toxic, pro-inflammatory
inclusions are thought to form the
molecular basis for the elevated oxida-
tive stress, aberrant immune-activation
and chronic inflammation characteris-
tic of AD brain (Armstrong, 2006; Cui
et al., 2007; Van Broeck et al., 2007;
Boutajangout and Wisniewski, 2013;
Furukawa and Nukina, 2013; Ferrera
et al., 2014; Serpente et al., 2014; Takeda
et al., 2014). Interestingly (i) βAPP-derived
Aβ42 peptides induce a pattern of expres-
sion of inflammatory genes typical of the
classical immune- and inflammatory-
response induced by infectious agents
such as bacterial lipopolysaccharide
(LPS), a common endotoxin of the outer
membrane of gram-negative bacteria
(Colangelo et al., 2002; Ferrera et al.,
2014), and (ii) the presence of bacteria,
LPS or endotoxin-mediated inflammation
strongly contributes to amyloid neurotox-
icity (Hammer et al., 2008; Dasari et al.,
2011; Blanco et al., 2012; Zhou et al., 2012;
Serpente et al., 2014).
CONGO RED STAINING TO IDENTIFY
AMYLOID DEPOSITS
Congo red [3,3′-([1,1′-biphenyl]-4,4′-
diyl)bis(4-aminonaphthalene-1-sulfonic-
acid-disodium salt)], a toxic, water soluble
secondary diazo dye, was first synthe-
sized in 1883 and used as a textile dye
(Steensma, 2001; Linke, 2006). Due to
its toxicity, Congo red’s use in textile
dying was discontinued, but because of
its important spectroscopic properties
gained wide use in investigative microbi-
ology (Linke, 2006). The proposed Congo
red-mediated staining mechanism sug-
gests a substrate-mediated hydrophobic
pi-pi orbital stacking interaction between
the aromatic rings of the dye molecules
and β-pleated sheet structures of both
amyloids and textiles (Buxbaum and
Linke, 2012). Congo red was classically
used in microbiological epidemiology as
a bacterial-stain, for example, to rapidly
identify the presence of virulent forms
of gram-negative Shigella where the dye
binds the bacterium’s unique LPS sur-
face structures (Linke, 2006; Buxbaum
and Linke, 2012). Congo red’s apple-green
birefringent fluorescence under polarized
light when bound to amyloid fibrils is
currently used as a sensitive diagnostic
tool for amyloidosis including the Aβ42-
enriched SPs of AD (Steensma, 2001;
Linke, 2006; Buxbaum and Linke, 2012).
Interestingly it has very recently been
found that (i) LPS is capable of inducing a
pathogenic Congo red-sensitive β-pleated
sheet conformation in prion amyloids
(Saleem et al., 2014); and (ii) the infec-
tious microbial burden is significantly
associated with both AD development
and the propensity of AD amyloids to
be stained by Congo red (Bu et al.,
2014).
MOLECULAR MIMICRY BETWEEN
MITOCHONDRIA AND BACTERIA
Because mitochondria appear to have
originated from bacteria via endosym-
biotic relationships that formed very early
in the evolutionary history of eukary-
otes, cross-reactivity of mitochondria and
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immunological responses to bacterial
amyloid or LPS may have deleteri-
ous effects on mitochondrial function.
This “molecular mimicry” is partially
evidenced by extragastric diseases such
as the basal ganglia disorder Sydenham’s
chorea, rheumatic fever, low-grade
systemic-inflammatory states and the
link to the Firmicute Streptococcus
and/or the gram-negative microaerophilic
Proteobacteria Helicobacter pylori
(Douglas-Escobar et al., 2013; Hayashi,
2013; Hornig, 2013; Roubaud Baudron
et al., 2013; Hill et al., 2014). Previous
bacterial infection resulting in antibody
formation to amyloids or bacterial endo-
toxins may predispose CNS mitochondria
or amyloids to subsequent attack by anti-
bodies resulting in the up-regulation of
inflammatory signaling (Bu et al., 2014).
ACTIVATION OF TLR2 BY AMYLOIDS
TLRs are type I membrane-spanning pro-
tein receptors expressed in microglial
cells. TLRs play key roles in host pro-
tection from microbial-invasion via the
activation of the innate-immune system
by sensing structurally conserved PAMPs
from microbes that are distinguishable
from, and not innate to, the host organ-
ism (Tükel et al., 2009; Harry, 2013;
Yu and Ye, 2014). Of the 13 currently
identified TLRs (TLR1 to TLR13) the
microglial TLR2s are activated by amy-
loid, lipoproteins and other microbial trig-
gers that subsequently induce cytokine
production, inflammation, phagocytosis
and innate immune defense responses
that directly impact CNS homoeostasis
and drive neuropathology. More specif-
ically the TLR2/TLR1 complex can rec-
ognize biofilm-associated amyloids pro-
duced by Firmicutes, Bacteroidetes, and
Proteobacteria (Nishimori et al., 2012;
Bhattacharjee and Lukiw, 2013; Asti and
Gioglio, 2014). Remarkably, the Aβ42
peptides of AD that are associated with
robust microglia-mediated inflammatory
responses also activate TLR2 (Gustot
et al., 2013; Yu and Ye, 2014). Of
further interest is (i) that microbial
amyloids induce pro-inflammatory inter-
leukin IL-17A, a driver of NF-kB signal-
ing and cyclooxygenase-2 activation, and
other potent mediators of inflammatory-
responses such as IL-22 via direct TLR2
activation (Nishimori et al., 2012); and
(ii) that increased levels of IL-17A and IL-
22 are associated with chronic inflamma-
tory diseases including AD (Zhang et al.,
2013).
CONCLUDING REMARKS
Diverse microbes of the human micro-
biome generate functional amyloids.
Their ability to bind Congo red has
provided useful tools for characterizing
both microbial- and CNS-derived amy-
loids (Zhou et al., 2012; Serpente et al.,
2014). The large amount of microbial-
generated GI amyloid implicates high
potential systemic exposure to bacterial
amyloid, and the bioavailability of amy-
loid to the CNS increases as humans age
(Bhattacharjee and Lukiw, 2013; Marques
et al., 2013; Tran and Greenwood-Van
Meerveld, 2013; Oakley and Tharakan,
2014). Microbial and CNS amyloids are
biologically similar in their structure and
immunogenicity and complex mecha-
nistic interrelationships between these
amyloids are beginning to emerge. It
is remarkable (i) that human microbes
that produce amyloids such as CsgA and
curli, and the Aβ42 peptides that accu-
mulate in AD, are recognized by the same
TLR2/TLR1 immune sensor-receptor sys-
tem of the 13 different TLR-type receptors
available; and (ii) that they direct the
same up-regulation of IL-17A- and IL-
22-mediated pro-inflammatory-signaling
(Rapsinski et al., 2013; Zhang et al., 2013;
Yu and Ye, 2014). Interestingly, CsgA and
Aβ42 peptides do not share common
amino-acid sequences, only structural
similarity in their PAMPs. Microbes or
their secretory or degradation products
including their amyloids and LPSs are
powerful inflammatory activators and
inducers of cytokines and complement
proteins, affecting vascular permeability
and generating free-radicals that fur-
ther support amyloidogenesis (Hill et al.,
2014; Lin et al., 2014). These pathogenic
signaling features are also highly charac-
teristic of AD neuropathology. A more
detailed understanding of human micro-
bial ecosystems and their amyloids should
give insight into amyloid-misfolding
and their contribution to inflammatory-
signaling in health, aging and disease. It
will certainly be interesting to see: (i) if any
microbial-generated amyloids co-localize
with the amyloid-dense SP deposits of AD;
(ii) if GI tract microbiome-derived amy-
loids become more available systemically
as humans age; and (iii)what the evolution
and nature of amyloid-related communi-
cation between the GI-tract and the CNS
has on the development or propagation
of amyloidogenesis in pro-inflammatory
degenerative disease.
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